Home › NDC Lookup › RxCUI directory › RxCUI 861045

1.5 ML pramlintide acetate 1 MG/ML Pen Injector [Symlin] — RxCUI 861045

Name: 1.5 ML pramlintide acetate 1 MG/ML Pen Injector [Symlin] (RxCUI 861045)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 861045 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI861045

Official name1.5 ML pramlintide acetate 1 MG/ML Pen Injector [Symlin]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as1.5 ML Symlin 1 MG/ML Pen Injector; SymlinPen 60 1000 MCG/ML in 1.5 ML Pen Injector; Symlin 1 MG/ML 1.5 ML Prefilled Pen; SymlinPen 60 1000 MCG per ML Pen Injector, 1.5 ML

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)67 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pramlintide Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

When you add pramlintide to your routine, both it and your insulin lower blood sugar at the same time — and together they can push your blood sugar dangerously low. Cutting your me...
Why do I have to cut my insulin dose when I start SymlinPen?
Yes, nausea is the most common side effect, especially in the first few weeks. The good news is that it tends to get better on its own as your body adjusts, particularly when the d...
I feel really nauseated after my injection — is that normal, and will it go away?

📖 Read our full Pramlintide Injection guide →

🕸️ Concept Web — How 1.5 ML pramlintide acetate 1 MG/ML Pen Injector... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1.5 ML pramlintide acetate 1 MG/ML Pen Injector [Symlin] RxCUI 861045 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Pramlintide 139953 IN
- Pramlintide acetate 356773 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Symlin 356774 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Pramlintide Pen Injector 1657563 SCDF
- Pramlintide acetate Pen Injector 2645328 SCDFP
- Pramlintide Injectable Product 1161690 SCDG
- Pramlintide acetate Injectable Product 2660359 SCDGP
- Pramlintide Pen Injector [Symlin] 1657565 SBDF
- Pramlintide acetate Pen Injector [Symlin] 2657409 SBDFP
- Symlin Injectable Product 1185508 SBDG
- Pen Injector 1649571 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1.5 ML pramlintide acetate 1 MG/ML Pen Injector 861044 SCD
- Pramlintide acetate 1 MG/ML 861034 SCDC
- Pramlintide acetate 1 MG/ML [Symlin] 861036 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1.5 ML pramlintide acetate 1 MG/ML Pen Injector SCD · 861044
Pramlintide acetate 1 MG/ML SCDC · 861034
Pramlintide Pen Injector SCDF · 1657563
Pramlintide acetate Pen Injector SCDFP · 2645328
Pramlintide Injectable Product SCDG · 1161690
Pramlintide acetate Injectable Product SCDGP · 2660359

Brand-Name Concepts

Pramlintide acetate 1 MG/ML [Symlin] SBDC · 861036
Pramlintide Pen Injector [Symlin] SBDF · 1657565
Pramlintide acetate Pen Injector [Symlin] SBDFP · 2657409
Symlin Injectable Product SBDG · 1185508
Symlin BN · 356774

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 861045 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00310-6615-02	2 CARTRIDGE in 1 CARTON (0310-6615-02) / 1.5 mL in 1 CARTRI...	SymlinPen	AstraZeneca Pharmaceuticals LP	2015-02-02
00310-6627-02	2 CARTRIDGE in 1 CARTON (0310-6627-02) / 2.7 mL in 1 CARTRI...	SymlinPen	AstraZeneca Pharmaceuticals LP	2015-01-08

Observed labelers: AstraZeneca Pharmaceuticals LP (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$274.2365

Range $217.5210–$330.9520 · middle 50% $245.8788–$302.5943 · 2 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.